1[1]Aravantinos G,Fountzilas G,Kosmidis P,et al.Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer:long-term efficacy results:a Hellenic Cooperative Oncology Group (HeCOG) study.Ann Oncol,2005,16:1116-1122.
2[2]Piccart MJ,Bertelsen K,James K,et al.Randomized inter group trial of cisplantin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer:three-year result.J Nstl Cancer Inst,2000,92:699-708.
3[3]Varia MA,Stehman FB,Bundy BN,et al.Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage Ⅲ ovarian carcinoma:a randomized trial of the Gynecologic Oncology Group.J Clin Oncol,2003,21:2849-2855.
4[4]Bertelsen K,Jakoobsen A,Stroyer J,et al.A respective randomized comparison of 6 and 12 cycles of cyclophosphamide,adriamycin,and cisplantin in advanced epithelial ovarian cancer:a Danish Ovarian Study Group (DACOVA) trial.Genecol Oncol,1993,49:30-36.
5[5]Umesaki N,Tanaka T,Muso H,et al.Intermittent cisplatin therapy for stage-Ⅲ ovarian cancer patients following clinical remission.Gynecol Obstet Invest,1999,47:139-143.
6[6]Markman M,Liu PY,Wilczynski S,et al.Phase Ⅲ randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy:a Southwest Oncology Group and Gynecologic Oncology Group trial.J Clin Oncol,2003,21:2460-2465.
7[7]Micha JP,Goldstein BH,Mattison JA,et al.Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin,paclitaxel,and gemcitabine in advanced ovarian cancer.Gynecol Oncol,2005,96:132-135.
9[9]Skinner EN,Boruta DM,Gehrig PA,et al.Consolidation therapy with weekly paclitaxel infusion in advanced epithelial ovarian cancer and primary peritoneal cancer:an extended follow-up.Gynecol Oncol,2005,98:59-62.
10[10]Bolis G,Scarfone G,Tateo S,et al.Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel.Gynecol Oncol,2001,80:13-15.
8Lanne E, Derolf AR, Bjorklund E. The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry atthe end 0fpost-remission chemotherapy[J]. Haematologica, 2006, 91: 5203-5205.
9Nelson R. Postconsolidation immunotherapy in leukaemia remission [J]. Lancet Oncol, 2006, 7:626-628.
10De Placido S, Scambia G, Di Vagno G. Topotecan compared with no therapy alter response to surgery and carboplatin/ paclitaxel in patients with ovarian cancer: Multicenter Italian TriMs in Ovarian Cancer (MITO-1)randomized study [J]. J Clin Oneol, 2004, 22(13):4247-4249.
